Join to access to all OVN content. Join for Free
Interim Impact The Rise of Fractional Medical Affairs Roles in Pharmas New Reality
fractional medical affairs roles interim positions gig economy in pharma pharmaceutical staffing trends fractional work benefits

Interim Impact The Rise of Fractional Medical Affairs Roles in Pharmas New Reality


Share This Article


Summary

In this episode, Tom Caravela and Daniel Snyder explore the rise of fractional medical affairs roles in the post-COVID era. They define interim and fractional positions, highlighting how they benefit both job seekers and companies. The discussion covers the increase in these roles, company utilization of interim talent, disadvantages, and compensation expectations, offering negotiation tips for candidates. They also discuss the future of fractional staffing, market trends, and the gig economy's impact on pharma and biotech. The episode ends with cost-effective strategies and gratitude to the audience.

Key Points

  • Fractional medical affairs roles offer a cost-effective solution for pharmaceutical companies to address specific project needs without committing to full-time hires. The rise in fractional positions is driven by economic uncertainties and the need for companies to streamline operations while still advancing critical projects. Engaging in fractional work can help professionals bridge employment gaps, expand their networks, and gain new therapeutic experience, making them more attractive in the job market.

Click for Source
fractional medical affairs roles, interim positions, gig economy in pharma, pharmaceutical staffing trends, fractional work benefits

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Article
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
OVN Avatar Forbes Books Press Release Official

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Explore OVN